An open-label study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection.

Pulmocide Ltd0 sites18 target enrollmentAugust 21, 2018

Overview

No summary available.

Registry

who.int

Start Date

August 21, 2018

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•1\. Subject must be male or female, aged 18 years inclusive or older (at the time of consent).
•2\. Subject must be willing and able to adhere to the restrictions and prohibitions required by this protocol.
•3\. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose and requirements of the study and that they are willing to participate.
•4\. A confirmed diagnosis of CF by standard criteria.
•5\. Subject is able to produce sputum.
•6\. A history of persistently positive A. fumigatus sputum cultures from at least 2 sputum samples in the last year, the most recent of which must have been within the last 6 months.
•7\. Subject must have a positive sputum fungal culture at screening with one or more colonies of A. fumigatus detected using a modified standard approach.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•1\. Any other disease or condition, which in the Investigator’s medical opinion would preclude the subject’s participation in a clinical trial.
•2\. Is taking inhaled amphotericin B or has taken it within 7 weeks of Day 1\.
•3\. Is taking systemic steroid treatment or has taken it within 4 weeks of Day 1\. Subjects considered to be stable on a systemic steroid dose of \<15 mg for at least a month will not be excluded.
•4\. Is taking systemic antifungal treatment (intravenous, oral or inhaled) or has received antifungal therapy (intravenous, oral or inhaled) within 6 weeks of Day 1\.
•5\. If female, the subject is pregnant (e.g., has a positive serum ß human chorionic gonadotropin (ß\-hCG) at screening or a positive urinary pregnancy test pre\-dose on Day 1\), lactating or breast feeding.
•6\. Any respiratory exacerbation within 2 weeks of the start of the study.
•7\. Any upper respiratory tract infection or signs or symptoms thereof within 2 weeks prior to dosing.
•8\. Positive culture for Mycobacterium abscessus within 12 months before screening or between screening and baseline, or currently receiving treatment for Mycobacterium abscessus.
•9\. Has chronic, active hepatitis or a positive hepatitis B surface antigen or positive hepatitis C antibody result at screening.
•10\. Is taking antiretroviral protease inhibitor therapy.